On September 25, GelonHui reported that Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary Hunan Sailong Pharmaceutical Co., Ltd. recently obtained the 'Notice of Approval for the Application for Listing of Hydrochloride Ivabradine as a Chemical Raw Material Drug' issued by the National Medical Products Administration.
The main indications for hydrochloride ivabradine formulations: used for the treatment of paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.